Wire · opportunities
FDA Expands Pirtobrutinib to First-Line Treatment of CLL/SLL Without 17p Deletion
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 2 October 2026 · Fusion42 review
The FDA has expanded the approved use of pirtobrutinib to include first-line treatment for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who do not have the 17p deletion mutation.
This Wire brief sits within Fusion42's coverage of Biotech, and 9 sources have reported it between 2 Oct 2026 and 6 Oct 2026.
◆ ◆ The Wire takeaway
You can now target a broader patient group with pirtobrutinib after the FDA expanded its use to first-line CLL/SLL without 17p deletion. This opens a new market window for therapeutic developers in leukemia treatment to accelerate adoption.
◆ Coverage
9 sources · first reported 2 Oct 2026 · latest 6 Oct 2026
◆ Topics